New Omega-3 Fish Oil: Beyond EPA and DHA, What Are Researchers Investigating?
For decades, fish oil supplements have been associated with two familiar omega-3 fatty acids: EPA and DHA. From heart health to brain development, these nutrients have dominated supplement labels, scientific discussions, and consumer purchasing decisions.
But researchers are now investigating a lesser-known group of omega-3 fatty acids that could expand our understanding of fish oil. A human clinical study sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is examining whether fish oil enriched with very-long-chain polyunsaturated fatty acids (VLC-PUFAs) produces different biological responses compared with DHA-rich fish oil.
What Makes This Fish Oil Different?
Traditional fish oil supplements primarily emphasize EPA and DHA, omega-3 fatty acids containing 20 and 22 carbon atoms, respectively.
Very-long-chain omega-3 fatty acids have longer molecular structures, generally containing 24 to 38 carbon atoms. Although these compounds occur naturally in certain tissues, including the retina, they are typically present in very small quantities in conventional fish oil.
The investigational formulation contains approximately ten times the amount of VLC-PUFAs found in conventional fish oils. Researchers want to determine whether this difference in composition affects how omega-3 fatty acids are absorbed, incorporated into blood cells, and processed by the body.
Why Did Scientists Become Interested in These Fatty Acids?
The scientific interest began before the latest clinical trial. A 2023 study, involving researchers from the NIH and other institutions, investigated fish oil enriched with VLC-PUFAs in mice. Researchers observed incorporation of these fatty acids into tissues including the liver, brain, and eyes.
The animals also showed favorable changes in certain cardiometabolic measurements and improvements in tests of retinal function. These findings suggested that VLC-PUFAs deserved further investigation, although animal results cannot establish equivalent benefits in humans.
Earlier research on human retinal tissue also identified associations between very-long-chain fatty acid composition and retinal health, providing another reason to investigate their biological importance.
What Is the New NIH Clinical Trial Investigating?
The clinical study, registered as NCT07882160, is titled “Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals.”
Researchers plan to enroll approximately 200 participants in a randomized, double-blind, crossover study. Participants will receive two fish oil capsules daily for eight weeks, followed by a 12-week break and another eight-week period using the alternative fish oil formulation.
What Will Researchers Measure?
The primary measurement is the Omega-3 Index, which represents the proportion of EPA and DHA in red blood cell fatty acids. Researchers will compare how this measurement changes with VLC-PUFA-enriched fish oil versus DHA-rich fish oil.
Additional assessments include blood lipid profiles, fatty acid metabolism, inflammatory markers, visual function, and cognitive testing. The study is designed to explore biological responses, not to establish that the experimental fish oil prevents heart attacks or treats eye disease.
Could This Change the Future of Omega-3 Supplements?
The possibility is scientifically interesting, but several important questions remain unanswered. Researchers still need to establish how effectively these fatty acids are absorbed in humans, whether they provide meaningful advantages over existing formulations, and whether their long-term use is beneficial and safe.
For now, established omega-3 research remains centered on EPA and DHA. According to the NIH Office of Dietary Supplements, these fatty acids can help reduce triglyceride levels, particularly in prescription-strength formulations used under medical supervision. Evidence concerning other cardiovascular outcomes varies by population and intervention.
What Should Consumers Know Before Buying Fish Oil?
The new study does not establish that VLC-PUFA-rich fish oil is superior to conventional supplements or that consumers should change their current omega-3 routine.
When comparing available products, EPA and DHA content, appropriate dosage, product quality, and individual health needs remain more useful considerations than experimental claims.
The important development is not a new miracle supplement. It is a scientific question entering human research: could the benefits and biological functions of fish oil extend beyond EPA and DHA?
For consumers, understanding existing omega-3 formulations is still the practical starting point. Explore our Best Omega-3 buying guide to learn how fish oil supplements differ.
